Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

Tmirah Haselkorn; David Mink; Farid Kianifard; Benjamin Ortiz; Brandee Paknis; Jason Lecocq; Bradley E. Chipps; Eugene R. Bleecker

doi:10.1016/j.anai.2021.08.005

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

Tmirah Haselkorn, David Mink, Farid Kianifard, Benjamin Ortiz, Brandee Paknis, Jason Lecocq, Bradley E. Chipps, Eugene R. Bleecker

Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	593-595
Number of pages	3
Journal	Annals of Allergy, Asthma and Immunology
Volume	127
Issue number	5
DOIs	https://doi.org/10.1016/j.anai.2021.08.005
State	Published - Nov 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.anai.2021.08.005

Cite this

@article{3d6b884d1e97464daf39dd66eb2e1554,

title = "Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort",

author = "Tmirah Haselkorn and David Mink and Farid Kianifard and Benjamin Ortiz and Brandee Paknis and Jason Lecocq and Chipps, {Bradley E.} and Bleecker, {Eugene R.}",

note = "Funding Information: Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California. Funding Information: We thank Chiranjit Ghosh, PhD, and Rahul Lad, PhD (Novartis), for providing medical writing support for this manuscript. We thank Dr Larry Borish, University of Virginia Health System, Charlottesville, Virginia, and Dr Scott T. Weiss, Channing Division of Network Services, Department of Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, for their contributions to the original analysis. Disclosures: Dr Haselkorn is a former consultant to Novartis Pharmaceuticals Corporation. Dr Ortiz is a former employee and stockholder of Novartis Pharmaceuticals Corporation. Mr Mink is an employee of ICON Clinical Research, a company that receives research funding from Genentech Inc., Novartis, and other pharmaceutical companies. Dr Kianifard, Dr Paknis, and Dr Lecocq are employees of Novartis Pharmaceuticals Corporation. Dr Bleecker reports having clinical trials through his employer, Wake Forest School of Medicine and The University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech Inc., Novartis, Regeneron, and Sanofi Genzyme; receiving personal fees from ERB; and serving as a paid consultant for ALK-Abello, AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, and Teva, outside of the submitted work. Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California.",

year = "2021",

month = nov,

doi = "10.1016/j.anai.2021.08.005",

language = "English (US)",

volume = "127",

pages = "593--595",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "5",

}

TY - JOUR

T1 - Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

AU - Haselkorn, Tmirah

AU - Mink, David

AU - Kianifard, Farid

AU - Ortiz, Benjamin

AU - Paknis, Brandee

AU - Lecocq, Jason

AU - Chipps, Bradley E.

AU - Bleecker, Eugene R.

N1 - Funding Information: Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California. Funding Information: We thank Chiranjit Ghosh, PhD, and Rahul Lad, PhD (Novartis), for providing medical writing support for this manuscript. We thank Dr Larry Borish, University of Virginia Health System, Charlottesville, Virginia, and Dr Scott T. Weiss, Channing Division of Network Services, Department of Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, for their contributions to the original analysis. Disclosures: Dr Haselkorn is a former consultant to Novartis Pharmaceuticals Corporation. Dr Ortiz is a former employee and stockholder of Novartis Pharmaceuticals Corporation. Mr Mink is an employee of ICON Clinical Research, a company that receives research funding from Genentech Inc., Novartis, and other pharmaceutical companies. Dr Kianifard, Dr Paknis, and Dr Lecocq are employees of Novartis Pharmaceuticals Corporation. Dr Bleecker reports having clinical trials through his employer, Wake Forest School of Medicine and The University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech Inc., Novartis, Regeneron, and Sanofi Genzyme; receiving personal fees from ERB; and serving as a paid consultant for ALK-Abello, AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, and Teva, outside of the submitted work. Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85113876549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113876549&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2021.08.005

DO - 10.1016/j.anai.2021.08.005

M3 - Article

C2 - 34391902

AN - SCOPUS:85113876549

SN - 1081-1206

VL - 127

SP - 593

EP - 595

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 5

ER -

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this